Boehringer's new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025
New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of Medicine
Data presented included an objective response rate (ORR) of 71%, with 7% of patients achieving complete responses (CR), and a 96% disease control rate (DCR)
Previously unreported results, including median duration of response (DoR) of 14.1 months and median progression-free survival (PFS) of 12.4 months, indicate the potential for zongertinib to impact clinical practice
Zongertinib continued to demonstrate a manageable safety profile, with low incidence of grade ≥3 drug-related AEs
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 days ago
- Cision Canada
Jiva Technologies First Purchase Order of LIV3's SugarShield Supplement Is Ready to Ship from Best Formulations and Will Begin Shipping Direct to Consumers by June 10, 2025
VANCOUVER, BC, June 5, 2025 /CNW/ -- Jiva Technologies (CSE: JIVA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("JIVA" or the "Company"), a leader in building niche online wellness communities and creating immersive physical environments, is pleased to announce that the first commercial production run of LIV3's SugarShield supplement is ready to ship from Best Formulations, a Sirio Group company. Fulfillment to consumers will begin on June 10, 2025, with pre-sale orders placed since the website's January launch transitioning to active shipping and standard orders opening thereafter. Best Formulations, a Sirio Group company renowned for producing some of the most recognized supplements in the United States, brings unparalleled expertise and quality assurance to this project. LIV3's SugarShield capsules feature a liposomal delivery system designed to enhance nutrient absorption and bioavailability, with benefits expected to be felt within as little as two weeks. Jiva believes that the e-commerce supplements category continues to expand rapidly, driven by increasing consumer demand for functional, science-backed products that support targeted wellness goals—from metabolic health to cognitive performance. The segment has seen significant growth as consumers prioritize convenience and transparency, with direct-to-consumer brands leading the charge. Lorne Rapkin, CEO of Jiva Technologies, commented: " is without question one of my favorite websites we've built at Jiva. I've been closely following the surge of new supplement brands launching GLP-1-inspired formulations and other wellness-forward solutions, and it's clear the world is ready for products that support better health outcomes in accessible ways. I believe that supplements are the fastest growing category in e-commerce right now, and partnering with Chris Mearns to launch SugarShield and oversee the entire digital strategy is a critical part of our vision to make wellness more attainable for everyone. I genuinely cannot wait for people to hold these jars in their hands and experience the results for themselves." This marks another milestone in Jiva's expanding portfolio of wellness-focused ventures, as the Company continues to leverage its digital expertise and consumer insights to build brands that connect with today's health-conscious audience. For more information about LIV3 or SugarShield, please visit About JIVA Technologies JIVA Technologies is dedicated to building niche online wellness communities and creating immersive physical environments. With a proven track record in e-commerce marketplaces, bolstered by expert UI/UX design and SEO, JIVA now focuses on joint ventures to support wellness brands in developing their online presence. The company owns and operates Bloombox Club, an online plant delivery marketplace serving the United States, Germany, the United Kingdom, Austria, the Republic of Ireland, France, Spain, and Italy, as well as The Locavore Bar and Grill, a vibrant dining and gathering destination in Squamish, BC. Recently, JIVA became a shareholder in VEG House, a leader in the plant-based space, through a share exchange agreement. Committed to e-commerce, marketing, and wellness, JIVA's mission is to cultivate online communities of like-minded consumers through education and collaboration. The company is actively pursuing joint ventures, such as the recently announced partnership with LIV3 for SugarShield, to empower wellness brands online by building their websites and managing all digital marketing. About LIV3 LIV3 is dedicated to improving metabolic health by addressing the detrimental effects of fructose through its flagship product, SugarShield. Originally introduced through where the product received overwhelmingly positive feedback for its efficacy, SugarShield features Luteolin, a powerful compound that blocks fructokinase. SugarShield has the potential to reduce cravings, boost energy, and support weight management by preventing fructose metabolism. This innovative approach allows individuals to experience the benefits of a sugar-free lifestyle without making drastic dietary changes. Backed by research, LIV3's solution targets the suspected root cause of metabolic dysfunction and offers a natural, effective way to improve overall health and wellness. About Best Formulations (a Sirio Company) Best Formulations, a Sirio Company, is a leading U.S.-based contract manufacturer specializing in high-quality dietary supplements, over-the-counter drugs, and functional foods. As part of the global Sirio Group—a renowned leader in the nutraceutical industry—Best Formulations combines international expertise with state-of-the-art manufacturing facilities in the United States. Committed to excellence and stringent quality control, the company adheres to strict U.S. regulatory standards and Good Manufacturing Practices (GMP), ensuring that products like SugarShield are manufactured to the highest quality. With over 35 years of industry experience, Best Formulations is dedicated to being a trusted partner in bringing innovative health products to market both domestically and internationally. Contact Lorne Rapkin Chief Executive Officer (416) 419-1415 Forward-looking Information This press release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may," "will," "expect," "likely", "should," "would," "plan," "anticipate," "intend," "potential," "proposed," "estimate," "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, statements regarding the availability of Future Farm products, JIVA promotional events and the business and strategic plans of the Company. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: receiving sufficient demand for the Offering; the Company's ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; the conflict in eastern Europe; having a limited operating history; the ability of the Company to access capital to meet future financing needs; the Company's reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions. Additional risk factors can also be found in the Company's continuous disclosure documents, which have been filed on SEDAR and can be accessed at Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained applicable herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by law.
Cision Canada
4 days ago
- Cision Canada
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert ® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment. Xpert ® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030. 1 "Xpert ® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy." The test is designed for use on any of Cepheid's GeneXpert ® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert ® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025. Visit for more information. Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578 About Cepheid Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit
Global News
5 days ago
- Global News
Weight-loss drug Wegovy use is up 50% among U.S. teens, study shows
American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows. The average rate of teens beginning treatment with the highly effective Novo Nordisk drug grew 50 per cent last year to 14.8 prescriptions per 100,000 adolescents, according to an analysis by health data firm Truveta. That's up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children aged 12 and older. The average rate climbed further during the first three months of this year, reaching 17.3 new prescriptions per 100,000. That still represents a minute fraction of the estimated 23,000 out of every 100,000 teens in the country who are living with obesity, and is far slower than the uptake among U.S. adults. Story continues below advertisement 'It's promising that more young people are using these medications, but it's still a very small percentage of patients with severe obesity that are getting access to them,' said Dr. Cate Varney, director of obesity medicine at the University of Virginia Health system. 'When lifestyle changes alone are insufficient, we need these additional tools.' 0:57 Zepbound vs. Wegovy: Which weight-loss medication comes out on top? For its analysis, Truveta reviewed the electronic health records of 1.3 million patients ages 12 through 17. The data covers 30 U.S. health systems with more than 900 hospitals and 20,000 clinics across the country. The analysis did not include other GLP-1 drugs, including Novo's Ozempic and Eli Lilly's Zepbound, which are not approved to treat obesity in adolescents, or compounded versions of these therapies. Story continues below advertisement Should teens use weight-loss drugs? Wegovy became an option to treat adolescents in late 2022 after decades in which the conventional approaches of diet, exercise and counseling largely failed. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy About eight million American teens, or 23 per cent of people ages 12 to 19, have obesity, up from five per cent in 1980, according to U.S. government data. Young people with obesity run a much higher risk of developing chronic, costly, life-shortening conditions like Type 2 diabetes and cardiovascular and liver diseases. 1:40 Microdosing Ozempic not recommended, doctors say In January 2023, the American Academy of Pediatrics strongly recommended that doctors provide weight-loss drugs to children with obesity starting at age 12. Yet the medical community has not uniformly embraced GLP-1s for adolescents. Story continues below advertisement Some doctors are hesitant because the drugs' long-term safety for children during a critical phase of development is unknown, and the treatments may need to be used indefinitely. Overall, there are limited options for many teens and their parents because insurance plans often do not cover any treatment for obesity, including intensive behavioral counseling, visits with a dietician or the new GLP-1 medications. At Nemours Children's Hospital in Wilmington, Delaware, the Healthy Weight and Wellness Clinic treated about 2,000 adolescent patients last year. About 25 per cent were prescribed Wegovy or another GLP-1 medication, said Dr. Thao-Ly Phan, the clinic's medical director. The number of adolescents with a GLP-1 prescription nearly doubled from 2023. Does it work? On average, their patients taking a GLP-1 drug lost 15 pounds (6.8 kg) within 6 to 12 months, and nearly 30 pounds after more than a year. Story continues below advertisement For many of the other patients, the medications were not an option, either because of insurance hurdles or concern within families about potential risks. Other teens opted for lifestyle changes or older, cheaper weight-loss drugs, with some success. 'It is important for us to continue to monitor and better understand outcomes from the medications – both positive and negative – before widespread use,' Phan said. 1:54 GLP-1 drugs like Ozempic, Wegovy reduce Alzheimer's risk for those with diabetes U.S. Health Secretary Robert F. Kennedy Jr. has criticized the idea of prescribing Ozempic or Wegovy widely to children to treat obesity. In a federal health report he released last month, GLP-1 drugs were cited as an example of the 'overmedicalization of our kids.' It noted a lack of 'long-term safety data, raising the specter of unforeseen problems that interrupt, damage, or impair metabolism and growth development.' Story continues below advertisement Novo in a statement said semaglutide, the active ingredient in Wegovy and Ozempic, 'did not appear to affect growth or pubertal development' during its clinical trials involving teens. For many adults, Novo said, obesity starts in childhood or adolescence, and 'we are confident in the proven safety and efficacy of our GLP-1 medicines.' Eli Lilly's weight-loss drug Zepbound is in late-stage clinical trials for use by adolescents. Lilly told Reuters that 'there has been no evidence to date suggesting impairment in growth or metabolism' from GLP-1 medications. Dr. Robert Siegel, a pediatrician and director of the Center for Better Health and Nutrition at Cincinnati Children's Hospital, said about 15 per cent of adolescents being treated there were prescribed Wegovy or a similar GLP-1 medication from July 2021 to July 2023. They include patients being treated for type 2 diabetes for which the GLP-1 drugs were originally developed. Siegel said he prefers to start teens on three to six months of intensive lifestyle management before even considering medication. While obesity specialists can help navigate potential risks from the drugs, many primary-care providers need more training, he said. They may not have the equipment to monitor for the loss of muscle mass – a side effect of these medicines – or lack the resources to work with families over an extended period on healthier eating and exercise. Story continues below advertisement 'These medications are likely to be needed for a very long time to maintain weight,' Siegel said, 'and we only have a relatively short-term experience with them.'
